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Abstract
Background: Snake bite is one of the most neglected public health issues in poor rural communities worldwide. In addition
to the clinical effects of envenoming, treatment with antivenom frequently causes serious adverse reactions, including
hypersensitivity reactions (including anaphylaxis) and pyrogenic reactions. We aimed to investigate the immune responses
to Sri Lankan snake envenoming (predominantly by Russell’s viper) and antivenom treatment.
Methodology/Principal Findings: Plasma concentrations of Interleukin (IL)-6, IL-10, tumor necrosis factor a (TNFa), soluble
TNF receptor I (sTNFRI), anaphylatoxins (C3a, C4a, C5a; markers of complement activation), mast cell tryptase (MCT), and
histamine were measured in 120 Sri Lankan snakebite victims, both before and after treatment with antivenom. Immune
mediator concentrations were correlated with envenoming features and the severity of antivenom-induced reactions
including anaphylaxis. Envenoming was associated with complement activation and increased cytokine concentrations prior
to antivenom administration, which correlated with non-specific systemic symptoms of envenoming but not with
coagulopathy or neurotoxicity. Typical hypersensitivity reactions to antivenom occurred in 77/120 patients (64%), satisfying
criteria for a diagnosis of anaphylaxis in 57/120 (48%). Pyrogenic reactions were observed in 32/120 patients (27%). All
patients had further elevations in cytokine concentrations, but not complement activation, after the administration of
antivenom, whether a reaction was noted to occur or not. Patients with anaphylaxis had significantly elevated
concentrations of MCT and histamine.
Conclusions/Significance: We have demonstrated that Sri Lankan snake envenoming is characterized by significant
complement activation and release of inflammatory mediators. Antivenom treatment further enhances the release of
inflammatory mediators in all patients, with anaphylactic reactions characterised by high levels of mast cell degranulation
but not further complement activation. Anaphylaxis is probably triggered by non allergen-specific activation of mast cells
and may be related to the quality of available antivenom preparations, as well as a priming effect from the immune
response to the venom itself.
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Introduction
Snake envenoming is a significant medical issue worldwide [1–
4]. It is a particular problem in South and Southeast Asia,
including Sri Lanka, where bites occur from a number of snakes,
most importantly Russell’s viper (Daboia russelii) [5–7]. Snake
venoms contain an array of proteins, toxins and enzymes that may
cause coagulopathy, neurotoxicity, myotoxicity, hypotension and
tissue necrosis [1]. In addition to direct toxic effects, in vitro studies
involving the addition of snake venom to human plasma have
shown activation of the complement cascade, with the generation
of anaphylatoxins (C3a, C4a, C5a), but these results have not been
confirmed in vivo in envenomed snakebite victims [8,9]. Studies of
mice injected with various snake venoms have demonstrated
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release of Interleukin-6 (IL-6), nitric oxide (NO), IL-5, tumor
necrosis factor-a (TNFa), IL-4, IL-10, prostaglandins and leuko-
trienes, with distinct time courses in production post venom
exposure for individual mediators [10–13]. A small number of
studies investigating plasma concentrations of proinflammatory
cytokines in envenomed humans have shown elevated concentra-
tions of IL-6, IL-8 and TNFa [14–16]. However, these studies
were performed on relatively small numbers of patients (n = 14–
26) and it remains unknown whether the release of immune
mediators contributes to the manifestations of envenoming or
simply reflects the degree of tissue damage.
Early systemic reactions to lyophilized equine polyvalent
antivenoms, such as those used in Sri Lanka and many other
tropical countries, have been reported to occur in up to 75% of
patients, with severe reactions (anaphylaxis) in up to 50% of those
treated [5–7,17,18]. Anaphylaxis is classified as either immune-
mediated or non-immune-mediated, with immune-mediated
further classified as IgE-dependent or non-IgE dependent [19].
IgE-dependent anaphylaxis, where allergen exposure results in
crosslinking of allergen-specific IgE bound to the surface of mast
cells which subsequently degranulate and release mast cell tryptase
(MCT) and histamine, requires prior exposure to the allergen.
However, this is unlikely to occur with antivenom because the
majority of snakebite victims have not been previously treated.
Complement activation by aggregates of immunoglobulins and/or
other proteins has therefore been proposed as the principal
mechanism underlying early reactions, largely on the basis of in
vitro studies [1,20,21]. The complement system may be activated
by envenoming, but no evidence of further complement activation
after antivenom treatment has been found in clinical studies
[22,23], and purification to reduce anti-complementary activity
does not appear to lower reaction rates [24]. Unlike IgE-
dependent anaphylaxis, rigors and fevers are prominent during
early antivenom reactions [18], with pyrogens (endotoxins)
introduced by poor production processes implicated in these
reactions.
We have previously reported elevated serum/plasma concen-
trations of MCT, histamine, IL-6, IL-10 and the soluble TNF
receptor I (sTNFRI) in patients presenting to the Emergency
Department with anaphylaxis triggered by foods, insect stings or
drugs (predominantly antibiotics and non-steroidal anti-inflam-
matory drugs (NSAIDs)) [25]. We therefore aimed to investigate
both the immune response to envenoming and the mechanisms of
adverse reactions to antivenom by measuring markers of
complement activation, mast cell degranulation and inflammation.
Methods
Samples were collected from patients enrolled in a randomized
clinical trial comparing two infusion rates of Indian polyvalent
antivenom (Bharat Serums and Vaccines Limited, India) for snake
envenoming in Sri Lanka which has been described in detail
elsewhere [5]. Not all patients in the trial had samples collected.
Sample collection was based on logistical considerations (staff
availability), not according to whether a reaction occurred.
Ethics Statement
The study was approved by the Ethical Review Committee,
Faculty of Medicine, University of Colombo and was registered
with the Sri Lanka Clinical Trials Registry, SLCTR/2007/005.
All patients gave written and informed consent to the study. For
patients between 14–18 years, written informed consent was
obtained from the patient’s parents/guardians as well as from the
patients themselves.
Study Patients
Patients were recruited from a secondary referral hospital in
Chilaw, Sri Lanka between 21st January 2007 and 31st July 2009.
Patients $14 years requiring treatment with snake antivenom
were eligible for inclusion. Patients administered antivenom prior
to recruitment to the study were excluded. After commencing
antivenom (10 vials of polyvalent antivenom (Bharat Serums and
Vaccines Limited, India) in 500 ml normal saline), patients were
observed for four hours for evidence of a systemic hypersensitivity
reaction. Blood was collected into EDTA tubes prior to antivenom
administration and then 15 minutes, 2 hours, 6 hours, 12 hours
and 24 hours after antivenom administration. Samples were
immediately centrifuged and the plasma aliquoted and frozen.
Data Collection
Demographic information, details of the bite, information on
snake identification, clinical features of envenoming, treatments
and outcomes were recorded. Baseline observations were recorded
prior to antivenom administration. The clinical features of early
reactions to antivenom were recorded along with blood pressure,
heart rate, respiratory rate and pulse oximetry readings.
Clinical envenoming syndrome(s) were defined in each patient
as venom induced consumption coagulopathy (INR.1.5), neuro-
toxicity (ptosis, diplopia, bulbar paralysis, limb weakness and/or
respiratory muscle paralysis) or non-specific systemic symptoms
(nausea, vomiting, headache, abdominal pain, diarrhoea). The
type of snake was based on identification of the snake by the
patient or clinician, and confirmed by enzyme immunoassay (EIA)
for Russell’s viper cases [26].
Classification of Reactions
Adverse reactions to antivenom were classified as hypersensi-
tivity reactions as we observed ‘‘objectively reproducible symptoms
Author Summary
Snakebites cause life-threatening symptoms including
uncontrolled bleeding and paralysis. The body’s immune
responses to snake venom may contribute to the severity
of these symptoms but have not been well characterized
in humans. Treatment with antivenom is potentially
lifesaving, but also carries risk, as severe allergic reactions
(anaphylaxis) are common. Anaphylaxis occurs when mast
cells, triggered by either allergen-specific antibodies, other
immunological mechanisms, or non-immune mechanisms,
release mediators that cause skin rashes, shortness of
breath and, in severe cases, life-threatening hypotension
and/or hypoxia. We have studied 120 snakebite victims in
Sri Lanka, both before and after treatment with antivenom.
Our results have shown snakebite triggers activation of the
complement cascade (an important part of the body’s
innate immune defence) and production of proinflamma-
tory mediators. In addition, we have demonstrated a quite
astonishing level of immune activation after antivenom
treatment in virtually every person treated, regardless of
whether they had a reaction to the antivenom. Half of the
patients treated experienced anaphylaxis, with clear
evidence of mast cell activation. Anaphylaxis to antivenom
is unlikely to be triggered by allergen-specific antibodies,
as patients had not been previously exposed to anti-
venom, but may be related to the quality of available
antivenom preparations, as well as a priming effect from
the immune response to the venom itself.
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or signs, initiated by exposure to a defined stimulus at a dose
tolerated by normal subjects’’ [27]. The use of the term
hypersensitivity does not imply previous exposure to antivenom.
Systemic hypersensitivity reactions were defined by typical skin
manifestations (urticaria/erythema) or National Institute of
Allergy and Infectious Diseases/Food Allergy and Anaphylaxis
Network (NIAID-FAAN) diagnostic criteria for anaphylaxis [28],
which recognise that some reactions may occur in the absence of
typical skin features. Our adaptation of this system is presented in
Table 1. Because gastrointestinal symptoms were a common effect
of envenoming, only new and persistent gastrointestinal symptoms
were included in the NIAID-FAAN Definition 2 for the purposes
of this study. We also added a further classification of respiratory
reactions (Definition 4) to account for the severe respiratory
reactions sometimes noted to occur without typical skin features.
These reactions were distinguished from those arising from
respiratory paralysis because they were not preceded by a
descending paralysis and result in primary hypoxia rather than
hypoxia secondary to ventilator failure. Reactions were graded as
skin only (which does not correspond with a diagnosis of
anaphylaxis), moderate anaphylaxis or severe anaphylaxis if
hypotension or hypoxia was observed during the course of a
hypersensitivity reaction [29]. Pyrogenic reactions (rigors and/or
fever) were coded separately and not included in the hypersen-
sitivity reaction grading system.
Treatment of anaphylactic reactions was directed by the
attending physician and most commonly involved a combination
of parenteral adrenaline (0.25 to 1 mg), corticosteroids (hydrocor-
tisone) and H1-antagonists.
Laboratory Assays
Plasma concentrations of MCT, histamine, IL-6, IL-10,
sTNFRI and TNFa, were measured as described previously
[25]. MCT concentrations in plasma were analyzed using the
Phadia ImmunoCAP system. MCT results greater than 11.4 ng/
ml are considered positive by this system, however we also assessed
change in MCT (DMCT) with a positive MCT result regarded as
a deviation of 2.0 mg/L (ng/ml) between high and low values for
each case as measured over time [30]. Histamine concentrations
were determined using IBL Histamine ELISA Kits according to
the manufacturer’s instructions (IBL, Hamburg, Germany).
Plasma samples were analyzed for IL-6, IL-10, sTNFRI and
TNFa using Flex Sets (BD Biosciences, San Jose, USA). Plasma
levels of C3a, C4a and C5a were determined using the
Anaphylatoxin CBA Kit from BD Biosciences. We defined a
positive result (.upper limit) as a concentration greater than the
99th centile of healthy control samples (n = 34) in our laboratory.
Statistical Methods
Data are presented as median (interquartile range; IQR).
Because of the skewed distributions of mediator concentrations,
non-parametric tests were applied to non-transformed (raw) data.
The measured baseline and peak mediator concentrations were
compared across all groups using the Kruskal-Wallis test and
between two groups using the Wilcoxon rank-sum (Mann-
Whitney) test. Matched data pairs (i.e. baseline versus peak) were
compared using the Wilcoxon signed-rank test. Correlations
between baseline and peak mediator concentrations were assessed
with Spearman rank correlation and Bonferroni adjustments were
applied for multiple simultaneous testing. The semi-parametric
lowess smoothing procedure was used to illustrate the relationship
between time from antivenom and the concentration of each
mediator. Statistical analysis was performed with Stata version
10.1 (StataCorp, College Station, Texas).
Table 1. Classification of hypersensitivity reactions.
Skin-only reaction: Generalised itch, erythema, urticaria, or angioedema without any sentinel features (see below) of other organ involvement
Anaphylaxis (based on NIAID-FAAN clinical criteria)
Definition 1: Any skin feature listed above plus at least one sentinel feature from either the respiratory or cardiovascular system (see below)
Definition 2: Sentinel features from two or more organ systems:
1. Skin – any of; generalised itch, erythema, urticaria, angioedema
2. Respiratory – any of; dyspnea, wheeze, stridor, throat tightness, hypoxemia (cyanosis or SpO2 #92%)
3. Cardiovascular – new onset of absolute hypotension (SBP,90 mmHg)
4. Gastrointestinal – new and persistent onset of any of; cramping abdominal pain, nausea, vomiting
Definition 3: Cardiovascular compromise only - new onset of absolute hypotension (SBP,90 mmHg)
Definition 4: Respiratory compromise only, any of; dyspnea, wheeze, stridor, hypoxemia (cyanosis or SpO2 #92%) not attributable to paralysis
Anaphylaxis Severity: Reactions meeting definitions 1–4 above were further classified as ‘‘severe’’ if there was hypoxemia or hypotension; otherwise reactions were
designated ‘‘moderate’’ severity.
doi:10.1371/journal.pntd.0002326.t001
Table 2. Baseline characteristics of 120 envenomed patients.
Age (yrs) 38 (27–49)*
Male, n (%) 90 (75%)
Snake, n (%)
Russell’s Viper 113 (94%)
Cobra 1 (1%)
Krait 1 (1%)
Unknown 5 (4%)
Time from bite (minutes)
To first blood sample 136 (96–209)*
To first antivenom 193 (150–270)*
Treatment A,{ n (%) 64 (53%)
*Median (interquartile range).
{Treatment A is 20 minute infusion rate vs Treatment B 2 hr infusion rate.
doi:10.1371/journal.pntd.0002326.t002
Immune Response to Snake Envenoming and Antivenom
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Results
Patient Demographics and Reaction Characteristics
Of 1004 patients presenting with suspected snakebites during
the study period, 247 patients received antivenom. One hundred
and ninety eight were randomised to receive antivenom by their
allocated infusion rate, and of these, 120 patients had blood
samples collected for this study. Baseline characteristics for these
patients are presented in Table 2. INR results were available for
112/120 patients, with 111/112 patients presenting with coagu-
lopathy (INR.1.5). The median value for the maximum INR
measured was 7.0 (IQR 3.7–13). Signs of neurotoxicity were
present in 72/120 (60%) patients and non-specific systemic
symptoms were observed in 91/120 (76%) patients. Eighty-six
patients bitten by Russell’s viper had pre-antivenom venom
concentrations measured, with a median of 171(IQR 85–399) ng/
ml. Thirty-three patients received a second dose of antivenom a
median of 8 (IQR 7–13) hours after the first dose, and six of these
patients received a third dose of antivenom.
Hypersensitivity reactions after the initial dose of antivenom
occurred in 77/120 (64%) patients, including 20/120 (17%) with
skin-only reactions and 57/120 (48%) with anaphylaxis. All
reactions occurred within the first four hours of starting antivenom
treatment. Cases of anaphylaxis satisfied Definition 1 in 32/57
(56%), Definition 2 in 11/57 (19%), Definition 3 in 6/57 (11%)
and Definition 4 in 8/57 (14%). Severe anaphylaxis was observed
in 51/57 (89%) anaphylaxis cases, of which 21/51 (41%) were
hypotensive, 18/51 (35%) were hypoxemic and 12/51 (24%) were
both hypotensive and hypoxaemic. As reported previously, there
was no difference in hypersensitivity reaction rates between the
two study arms (i.e. 20 minute vs 2 hour antivenom infusion rate)
[5]. Pyrogenic reactions were observed in 32/120 patients (27%),
10/32 (31%) reactions were pyrogenic alone and 22/32 (69%) had
a pyrogenic reaction in addition to a hypersensitivity reaction (1
skin-only, 21 anaphylaxis). Pyrogenic reactions were seen more
often in patients with anaphylaxis (21/57, 41%) compared to those
without (11/63, 17%).
Pre-antivenom Mediator Concentrations
A comparison between pre-antivenom mediator concentrations
in envenomed patients and healthy controls is shown in Table 3.
Almost all patients with snake envenoming had evidence of
complement activation before receiving antivenom, with plasma
concentrations of C3a elevated above the 99th centile of normal in
91% of patients. Plasma concentrations of IL-6, IL-10, C4a and
C5a were also significantly higher in envenomed patients before
they received antivenom. Although plasma concentrations of
MCT were greater than the 99th centile of our healthy control
group in 31% of envenomed patients, only 13/120 (11%) patients
had MCT concentrations above 11.4 ng/ml, the upper limit of
normal defined by the assay (median 15 (IQR 13.9–28.6). Pre-
antivenom concentrations of histamine and sTNFRI were not
significantly elevated in envenomed patients compared to healthy
controls. The median and interquartile ranges for TNFa were zero
for both groups.
Pre-antivenom mediator concentrations did not correlate with
maximum INR or pre-antivenom serum venom concentrations
(p.0.5 for all comparisons, Spearman’s). Patients with signs of
neurotoxicity had similar pre-antivenom plasma concentrations of
all mediators when compared to patients without signs of
neurotoxicity (p.0.2 for all comparisons, Mann Whitney).
Patients with non-specific systemic symptoms of envenoming had
significantly higher pre-antivenom levels of IL-6, IL-10 and
sTNFRI compared to those without (median serum concentrations
of IL-6 [12.6 (IQR 0–31.9) versus 6.2 (IQR 0–19.5), p = 0.044], IL-
10 [29.6 (IQR 10.7–68.7) versus 7.6 (IQR 0–16.5), p,0.001] and
sTNFRI [2043 (IQR 1131–3257) versus 962 (IQR 603–1546),
p,0.001]). There was no significant difference in pre-antivenom
mediator levels between patients subsequently having no reaction
to antivenom and patients experiencing pyrogenic reactions and/
or anaphylaxis.
Mediator Concentrations after Antivenom
Changes in serum concentrations of all immune mediators
measured before and after treatment with antivenom are
illustrated in Figure 1 (MCT and histamine), Figure 2 (IL-6, IL-
10, TNFa and sTNFRI) and Figure 3 (C3a, C4a and C5a). As all
adverse reactions to the initial dose of antivenom occurred during
the first four hours of antivenom treatment, and second and third
doses of antivenom were administered at least four hours after the
initial dose for all patients, only patients with samples available
from the first four hours of antivenom treatment were used for
comparisons of baseline (pre-antivenom) and peak mediator
concentrations (post-antivenom) by Wilcoxon Signed Rank Test
(n = 98). There were significant increases (baseline versus peak) in
MCT in all patient groups, whereas histamine only increased
significantly during skin-only and anaphylactic reactions (Figure 1).
Following antivenom administration, peak levels of MCT and
Table 3. Mediator levels in envenomed patients compared to healthy controls.
Mediator Healthy controls (n =34) Envenomed Patients (n =120) prior to antivenom
Median (IQR) 99th centile* Median (IQR) n.99th centile P{
MCT (ng/ml) 3.4 (2.6–4.5) 7.4 6.3 (4.3–8.0) 36 (31%) ,0.001
Histamine (ng/ml) 0.6 (0.2–0.7) 1.2 0.3 (0.1–0.5) 4 (3%) 0.066
IL-6 (pg/mL) 0 (0–0) 7.4 10.3 (0–26.6) 70 (58%) ,0.001
IL-10 (pg/mL) 0 (0–3.3) 8.4 20.7 (6.8–57.7) 85 (71%) ,0.001
sTNFRI (pg/mL) 1460 (822–2493) 3773 1766 (994–2872) 14 (12%) 0.229
C3a (ng/ml) 42.2 (34.7–51.9) 101 1683 (1103–2674) 106 (91%) ,0.001
C4a (ng/ml) 820 (534–1091) 2250 1578 (1034–2834) 38 (32%) ,0.001
C5a (ng/ml) 7.9 (5.6–10.4) 18.6 27.3 (11.4–113) 73 (62%) ,0.001
*Calculated from assays conducted in our laboratory on healthy controls.
{P-value is Mann-Whitney Test comparing healthy controls and envenomed patients.
doi:10.1371/journal.pntd.0002326.t003
Immune Response to Snake Envenoming and Antivenom
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histamine were significantly higher in anaphylaxis cases than
patients with no reaction and patients with skin-only reactions
(Table 4). DMCT was positive in 77% of anaphylaxis cases, 56%
of skin-only reactions and 31% of patients with no reaction. The
proportion of anaphylaxis patients with a positive DMCT was
significantly higher than patients with no reaction (p,0.001,
Fisher’s Exact Test). In patients who had anaphylaxis, concentra-
tions of histamine returned to baseline levels between 5–10 hours
after the initial dose of antivenom whereas concentrations of MCT
remained elevated in some patients for up to 24 hours (Figure 1).
Plasma concentrations of IL-6, IL-10, TNFa and sTNFRI all
increased significantly after antivenom compared with baseline in
all patient groups with the exception of TNFa and sTNFRI in
skin-only reactions (Figure 2). However, peak mediator concen-
trations were not different between patients with no reaction, skin-
only reactions and anaphylaxis (Table 4). In patients who had
anaphylaxis, concentrations of IL-6 and IL-10 remained elevated
for up to 24 hours after the initial dose of antivenom, whereas
concentrations of TNFa and sTNFRI returned to baseline levels
between 10–15 hours after the initial dose of antivenom (Figure 2).
Figure 3 demonstrates that plasma concentrations of C3a, C4a
and C5a were significantly elevated above healthy control levels
prior to antivenom, but did not increase significantly in any patient
group after administration of antivenom. There were no
significant differences in peak concentrations of C3a, C4a and
C5a between groups (Table 4).
In agreement with our finding that there was no difference in
hypersensitivity reaction rates between the two study arms (i.e.
20 minute vs 2 hour antivenom infusion rate), there was also no
significant difference in serum concentrations for any immune
mediator measured between the different infusion rates.
Mediator Concentrations and Pyrogenic Reactions
When all patients were considered together, patients who had
pyrogenic reactions to the antivenom had significantly higher peak
concentrations of IL-6, IL-10, TNFa and sTNFRI than patients
without pyrogenic reactions (data not shown). A confounding
factor was that patients with pyrogenic reactions were also more
likely to have anaphylaxis. Patients with pyrogenic reactions alone
had significantly higher peak levels of IL-6, IL-10 and sTNFRI
compared to patients with no reaction (pyrogenic or hypersensi-
tivity) (Table S1). Similarly, patients with both pyrogenic reactions
and anaphylaxis had significantly higher peak concentrations of
IL-6, IL-10, TNFa and sTNFRI compared to patients with severe
anaphylaxis alone.
Discussion
We found that envenoming by Sri Lankan snakes (predomi-
nantly D. russelii, Russell’s viper) causes significant immune
activation with elevated concentrations of MCT, IL-6, IL-10,
C3a, C4a and C5a compared to healthy controls, but without
clinical evidence of anaphylaxis to the venom. The pre-antivenom
concentrations of IL-6, IL-10 and sTNFRI correlated with the
non-specific systemic symptoms of envenoming which included
nausea, vomiting, headache, abdominal pain and diarrhoea. After
treatment with antivenom there were no further changes in C3a,
C4a and C5a, but there were rapid increases in IL-6, IL-10, TNFa
and sTNFRI concentrations, even when no hypersensitivity
reaction to antivenom occurred. These increases were highest in
patients who also had pyrogenic reactions. Patients experiencing
anaphylaxis also had rapid increases in plasma concentrations of
MCT and histamine, with significantly higher increases compared
to patients with no reaction to antivenom.
As it would be unethical to have an envenomed control group
that did not receive antivenom, an on-going effect of the venom
cannot be ruled out as a cause of the increase in cytokine levels
after treatment. However, the dramatic nature of the increase,
timed with antivenom administration rather than time from bite,
and correlations with the severity of hypersensitivity reactions both
Figure 1. Changes in MCT and histamine concentrations during treatment with antivenom. Lowess curve (thick dash-dot line). Upper
limit (99th centile healthy control values from our laboratory) (thin dashed line). Normal limit defined by assay (MCT only) (thin dotted line). * p-value
for difference between pre-antivenom concentration and peak concentration during the first four hours post-antivenom (Wilcoxon Signed Rank Test).
doi:10.1371/journal.pntd.0002326.g001
Immune Response to Snake Envenoming and Antivenom
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strongly suggest that the increase reflects an immune response to
antivenom in addition to that caused by the envenoming.
Treatment with antivenom is well known to trigger hypersen-
sitivity reactions. Almost half of the patients in this study
experienced severe anaphylaxis, characterised by hypoxia and/
or hypotension. We observed significant increases in both MCT
and histamine concentrations, correlating with the severity of the
hypersensitivity reaction. This confirms a role for mast cells and/
or basophils in the development of anaphylaxis after antivenom
treatment, however, the mechanism of activation by antivenom
remains to be elucidated. We observed no increase in C5a, C4a or
C3a after treatment with antivenom, with plasma levels remaining
steady or declining in the majority of patients post-antivenom.
This contradicts previous theories, based on in vitro studies, of mast
cell degranulation during anaphylaxis to snake antivenoms being
caused by complement activation and subsequent binding of
anaphylatoxins to their receptors on mast cells [1,20,21].
Therefore, the mechanism of mast cell activation during
hypersensitivity reactions to antivenom remains to be elucidated.
It is highly unlikely that the reactions are allergen-specific IgG or
IgE-mediated reactions, because patients rarely have the prior
exposure to antivenom that is required to generate allergen-
specific antibodies. Repeat exposure to antivenom is very rare in
most parts of the world where snake bites are due to unintentional
Figure 2. Changes in IL-6, IL-10, TNFa and sTNFRI concentrations during treatment with antivenom. Lowess curve (thick dash-dot line).
Upper limit (99th centile healthy control values from our laboratory) (thin dashed line). * p-value for difference between pre-antivenom concentration
and peak concentration during the first four hours post-antivenom (Wilcoxon Signed Rank Test).
doi:10.1371/journal.pntd.0002326.g002
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Figure 3. Changes in anaphylatoxin (C3a, C4a and C5a) concentrations during treatment with antivenom. Lowess curve (thick dash-dot
line). Upper limit (99th centile healthy control values from our laboratory) (thin dashed line). There were no significant differences between pre-
antivenom concentrations and peak concentrations during the first four hours post-antivenom for C3a, C4a or C5a (p.0.13 for all comparisons,
Wilcoxon Signed Rank Test).
doi:10.1371/journal.pntd.0002326.g003
Table 4. Peak mediator levels within the first four hours post-antivenom; comparisons between no reaction, skin-only reactions
and anaphylaxis.
Mediator No reaction (n=35) Skin only reactions (n=17) Anaphylaxis (n=46)
Median (IQR) n.99th centile* Median (IQR)
n.99th
centile* Median (IQR)
n.99th
centile*
MCT (ng/ml){ 7.1 (4.5–9.5) 13 (41%) 9.9 (6.8–28.1) 13 (76%) 24.7 (11.3–49.9) 37 (80%)
Histamine (ng/ml)` 0.4 (0.2–0.5) 3 (9%) 0.5 (0.3–1.2) 4 (24%) 1.0 (0.4–4.1) 22 (48%)
IL-6 (pg/mL) 280 (24.6–2136) 32 (91%) 154 (25.4–1531) 17 (100%) 432 (27.8–9123) 45 (98%)
IL-10 (pg/mL) 342 (55.2–937) 32 (91%) 197 (19.1–929) 15 (88%) 606 (71.2–3499) 42 (91%)
TNFa (pg/mL) 0 (0–0) 7 (20%) 0 (0–0) 0 (0%) 0 (0–11.9) 12 (26%)
sTNFRI (pg/mL) 3476 (2296–5486) 14 (40%) 2296 (1489–5098) 6 (35%) 3362 (1602–7147) 20 (43%)
C3a (ng/ml) 2039 (894–2700) 30 (88%) 1442 (956–3032) 13 (81%) 1627 (1149–2463) 41 (89%)
C4a (ng/ml) 1516 (933–2857) 13 (38%) 1384 (597–2388) 5 (31%) 1604 (800–2489) 14 (30%)
C5a (ng/ml) 26.3 (7.7–197) 18 (53%) 23.2 (14.4–217) 10 (63%) 28.0 (14.4–95.4) 29 (63%)
*Calculated from assays conducted in our laboratory on healthy controls.
{p,0.001 comparing all groups (Kruskal-Wallis), p,0.001 for anaphylaxis versus no reaction, p = 0.050 for anaphylaxis versus skin-only reaction (Mann Whitney).
`p,0.001 comparing all groups (Kruskal-Wallis), p,0.001 for anaphylaxis versus no reaction, p = 0.064 for anaphylaxis versus skin-only reaction (Mann Whitney).
doi:10.1371/journal.pntd.0002326.t004
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encounters with snakes, unlike developed countries where snake
handlers often have prior exposure [31]. Interestingly, reactions to
snake antivenom are not more common in snake handlers, again
supporting that reactions are not allergen-specific IgG or IgE-
mediated. However, anaphylaxis may be triggered by non-allergen
specific cross-linking of IgE bound to the surface of mast cells and
basophils. For examples, potato lectin has been shown to activate
and degranulate both mast cells and basophils by cross-linking cell
bound IgE, which contains 10–12% carbohydrates, through
interactions with IgE glycans [32]. A similar mechanism of non-
allergen specific IgE-triggered anaphylaxis has been proposed for
X-ray contrast media reactions, with the hypothesis that contrast
media may bridge adjacent IgE molecules via non-specific
attachment to their Fc segments [33]. Similarly, it is possible that
antivenoms may contain aggregates of immunoglobulins and/or
other proteins that have the ability to crosslink IgE receptors on
the surface of mast cells resulting in non-allergen specific mast cell
degranulation.
Activation of mast cells via IgG receptors has long been
proposed as a mechanism for antivenom-induced anaphylaxis.
Studies of cultured human mast cells have demonstrated that IgG
aggregates can activate mast cells [34], and histamine is released
after IgG-receptor FccRIIA aggregation [35]. Most of these
models have required an antigen-specific response and such a
mechanism is unlikely in this setting for the reasons outlined
above. However, heat-aggregated IgG1 (i.e. without the presence
of specific antigen) can activate IFNc-treated human mast cells
and this effect is enhanced in the presence of C3a [36]. It is
therefore plausible that the immune response to snake venom,
including elevated levels of C3a observed in this study, primes cells
to degranulate in response to microaggregates of IgG that may be
present in antivenom preparations. This may be more likely in
preparations that are reconstituted after lyophilisation, if the
antivenom (IgG) does not completely dissolve.
Mast cell activation can also occur via a number of other
mechanisms, including engagement of receptors for ligands such as
chemokines and cytokines, sphingosine 1-phosphate (S1P) and
platelet activating factor (PAF) [37–40]. An interesting observation
in this study was that prior to administration of antivenom there
was already evidence of immune activation, including high
concentrations of cytokines that are produced during anaphylaxis
[25]. A proportion of envenomed patients also had clear evidence
of mast cell degranulation prior to treatment with antivenom, with
elevated baseline concentrations of MCT above normal range in
31%. Histamine concentrations were increased above normal
range in some cases but this did not reach statistical significance,
which may reflect poorer sensitivity of this assay for low levels of
mast cell activation. In a mouse model, Metz et al found that mast
cells significantly reduce snake-venom-induced pathology, by
releasing carboxypeptidase A and possibly other proteases, which
can degrade venom components [41]. This probably reflects an
innate response to ‘‘dangerous’’ molecular patterns, reflecting the
evolution of mast cells to provide a protective role against a range
of noxious environmental toxins including venoms [42]. Thus,
snake venom-induced activation of mast cells and the release of
potent biologically active mediators has been proposed to
contribute to the symptoms of envenoming, including local
inflammation, vascular permeability (oedema) and shock [12]. It
is possible that mast cell activation and the induction of cytokine
and anaphylatoxin production by venom also primes cells to react
to antivenom.
Pyrogenic reactions, including shivering and sweating, occurred
in 32 patients, 10 with no other features of immediate
hypersensitivity reaction based on our criteria (Table 1). Pyrogenic
reactions to antivenom are thought to be caused by contamination
of the antivenom preparation by endotoxin or lipopolysaccharide
(LPS). Bacterial contamination of antivenom may also contribute
to the development of anaphylaxis as LPS can directly activate
mast cells [43]. Therefore, ensuring sterile manufacturing practises
and filtering or heat-treating antivenom preparations may reduce
both hypersensitivity and pyrogenic reactions [44].
We have demonstrated that Sri Lankan snake envenoming is
characterized by significant complement activation and release of
inflammatory mediators. Antivenom treatment then intensifies this
immune response, resulting in anaphylaxis characterized by high
levels of mast cell degranulation in almost half of cases. It is
unlikely antivenom reactions are triggered by allergen-specific IgG
or IgE. However, we did not observe an increase in C3a, C4a or
C5a after administration of antivenom, suggesting anaphylaxis to
antivenom is also not triggered by anaphylatoxins binding to their
receptors on mast cells and triggering degranulation as previously
proposed. Antivenom reactions may be triggered by immunogolu-
blin or proteins complexes present in the antivenom binding to
IgG receptors or non-specifically crosslinking IgE on the surface of
mast cells. This effect may be related to the quality of available
antivenom preparations, as well as a priming effect from immune
responses to the venom itself, including venom-induced mast cell
degranulation in some patients.
Supporting Information
Table S1 Patients who had pyrogenic reactions had
higher plasma concentrations of IL-6, IL-10 and sTNFRI
compared to patients without pyrogenic reactions in
both patients with anaphylaxis and patients with no
reaction to antivenom. Concentrations of TNFa were also
higher in patients with both pyrogenic and anaphylactic reactions
to antivenom compared to anaphylaxis alone. * Mediator
concentrations significantly higher in patients with pyrogenic
reactions (Mann-Whitney). { Mediator concentrations significantly
lower in patients with pyrogenic reactions (Mann-Whitney).
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